![Page 1: Biomarkers on tumor tissue: from research to diagnostic tools used in the Clinic](https://reader036.vdocuments.net/reader036/viewer/2022062501/56815cd0550346895dcae1bb/html5/thumbnails/1.jpg)
Biomarkers on tumor tissue: from research to diagnostic tools used in the Clinic
Bernard Têtu MDProfessor of PathologyLaval University
![Page 2: Biomarkers on tumor tissue: from research to diagnostic tools used in the Clinic](https://reader036.vdocuments.net/reader036/viewer/2022062501/56815cd0550346895dcae1bb/html5/thumbnails/2.jpg)
Conflict of interest
• Currently no conflict of interest to declare.• I have been consultant for Diagnocure until 2009
![Page 3: Biomarkers on tumor tissue: from research to diagnostic tools used in the Clinic](https://reader036.vdocuments.net/reader036/viewer/2022062501/56815cd0550346895dcae1bb/html5/thumbnails/3.jpg)
Biomarker Gutman et al. Nature reviews/cancer 2006; 6:565-571
• Definition:• « Any measurable diagnostic indicator that is used to assess the
risk or presence of disease. »
• FDA (diagnostic):• determining future risk of disease• screening for disease• confirming presence of disease• determining prognosis or staging• monitoring and/or optimizing treatment outcomes
• drug response• toxic reaction to drugs
![Page 4: Biomarkers on tumor tissue: from research to diagnostic tools used in the Clinic](https://reader036.vdocuments.net/reader036/viewer/2022062501/56815cd0550346895dcae1bb/html5/thumbnails/4.jpg)
Personalized medicine
• Biomarkers are expected to play an increasingly important role
• Cares must be efficient, safe, cost effective• integration of pharmaceutical and diagnostic activities
are expected to increase• We expect more tests to be performed by IHC in
pathology laboratories because of ease and low cost
![Page 5: Biomarkers on tumor tissue: from research to diagnostic tools used in the Clinic](https://reader036.vdocuments.net/reader036/viewer/2022062501/56815cd0550346895dcae1bb/html5/thumbnails/5.jpg)
Medical product development
Canada: Health Canada
Québec: Conseil du médicament
Tests in pathology
Ontario: QMP-LS / CCO
Québec: ?
![Page 6: Biomarkers on tumor tissue: from research to diagnostic tools used in the Clinic](https://reader036.vdocuments.net/reader036/viewer/2022062501/56815cd0550346895dcae1bb/html5/thumbnails/6.jpg)
Introduction of new tests on tumor tissue in pathology
• Many new tests are expected in the near future• Pathology laboratories are increasingly involved• Which laboratory should do the test?:
• Any laboratory interested at developing new tests?• Manufacturers which developed the test?• Ministry of health?
![Page 7: Biomarkers on tumor tissue: from research to diagnostic tools used in the Clinic](https://reader036.vdocuments.net/reader036/viewer/2022062501/56815cd0550346895dcae1bb/html5/thumbnails/7.jpg)
History of immunohistochemistry
• Early 1980 ’s: • first antibodies for clinical use
• 1980-2000: • antibodies mostly diagnostic or prognostic• ER/PR predictive
• 2000-: • FDA 32 Genomic Biomarkers in the Context of Approved Drug
Labels• Markers on tumor tissue in pathology:
• HER2/neu• EGFR• KIT• KRAS
![Page 8: Biomarkers on tumor tissue: from research to diagnostic tools used in the Clinic](https://reader036.vdocuments.net/reader036/viewer/2022062501/56815cd0550346895dcae1bb/html5/thumbnails/8.jpg)
Immunohistochemistry
• Type I: any test performed to determine cell differentiation and used for diagnostic purposes (most antibodies)
• Type II: tests not related to morphology and used for prognostic and predictive purposes (HER2/neu, ER/PR)
![Page 9: Biomarkers on tumor tissue: from research to diagnostic tools used in the Clinic](https://reader036.vdocuments.net/reader036/viewer/2022062501/56815cd0550346895dcae1bb/html5/thumbnails/9.jpg)
« For research use only »
![Page 10: Biomarkers on tumor tissue: from research to diagnostic tools used in the Clinic](https://reader036.vdocuments.net/reader036/viewer/2022062501/56815cd0550346895dcae1bb/html5/thumbnails/10.jpg)
Répertoire québécois et système de mesure des procédures de biologie médicale
![Page 11: Biomarkers on tumor tissue: from research to diagnostic tools used in the Clinic](https://reader036.vdocuments.net/reader036/viewer/2022062501/56815cd0550346895dcae1bb/html5/thumbnails/11.jpg)
Répertoire québécois et système de mesure des procédures de biologie médicale
![Page 12: Biomarkers on tumor tissue: from research to diagnostic tools used in the Clinic](https://reader036.vdocuments.net/reader036/viewer/2022062501/56815cd0550346895dcae1bb/html5/thumbnails/12.jpg)
Répertoire québécois et système de mesure des procédures de biologie médicale
![Page 13: Biomarkers on tumor tissue: from research to diagnostic tools used in the Clinic](https://reader036.vdocuments.net/reader036/viewer/2022062501/56815cd0550346895dcae1bb/html5/thumbnails/13.jpg)
Marker testing in Québec in 2009
• 58 pathology laboratories• 37 ER / PR by IHC• 21 HER2/neu by IHC• 5 HER2 by FISH
![Page 14: Biomarkers on tumor tissue: from research to diagnostic tools used in the Clinic](https://reader036.vdocuments.net/reader036/viewer/2022062501/56815cd0550346895dcae1bb/html5/thumbnails/14.jpg)
• ENSURING ACCESS TO HIGH QUALITY MOLECULAR ONCOLOGY LABORATORY TESTING AND CLINICALCANCER GENETIC SERVICES IN ONTARIO / Report of the Molecular Oncology Task Force | December 2008
• Recommendations: • 2) Implement a mandatory approval process for each genetic test performed
by laboratories in Ontario and administered by the appropriate regulatory agencies to ensure that only appropriately accredited and licensed laboratories with credentialed personnel are reporting and interpreting laboratory results that impact patient care.
• The following steps outline the Task Force’s proposed process for bringing new tests into clinical service.
• VI. The Ministry sets a reimbursement rate for the test and related clinical services.
• 6) Promote translational research and establish an “advance notice” process to ensure the system is prepared to implement new tests and technologies when evidence warrants.
Cancer Care Ontario
![Page 15: Biomarkers on tumor tissue: from research to diagnostic tools used in the Clinic](https://reader036.vdocuments.net/reader036/viewer/2022062501/56815cd0550346895dcae1bb/html5/thumbnails/15.jpg)
HER2/neu testing in Ontario
• overseen by QMP-LS/CCO ($$ per test)• 18 HER2/neu by IHC• 2 HER2 by FISH
9 testing sites
9 testing sites
Mount Sinai HospitalQA Ref. centre/Advanced testing centre
Sunnybrook & Women’sQA Ref. centre/Advanced testing centre
New site
New site
MOH & CCO
![Page 16: Biomarkers on tumor tissue: from research to diagnostic tools used in the Clinic](https://reader036.vdocuments.net/reader036/viewer/2022062501/56815cd0550346895dcae1bb/html5/thumbnails/16.jpg)
ASCO-CAP recommendations 2007 Canadian consensus on HER2/neu testing, 2007
ASCO-CAP Canadian consensus
![Page 17: Biomarkers on tumor tissue: from research to diagnostic tools used in the Clinic](https://reader036.vdocuments.net/reader036/viewer/2022062501/56815cd0550346895dcae1bb/html5/thumbnails/17.jpg)
ASCO-CAP recommendations 2007
![Page 18: Biomarkers on tumor tissue: from research to diagnostic tools used in the Clinic](https://reader036.vdocuments.net/reader036/viewer/2022062501/56815cd0550346895dcae1bb/html5/thumbnails/18.jpg)
Reproducibility HER2 testing Paik et al, J Nat Cancer Inst 94:852-854,2002
NSABPLocal laboratory % Concordance
positive casesTotal 79%small volume (<100/month) 76%Large volume 97%
![Page 19: Biomarkers on tumor tissue: from research to diagnostic tools used in the Clinic](https://reader036.vdocuments.net/reader036/viewer/2022062501/56815cd0550346895dcae1bb/html5/thumbnails/19.jpg)
CEPO (Comité de l’Évolution des Pratiques en Oncologie) recommendations, 2005
• use of trastuzumab for the adjuvant treatment of invasive breast cancers.
• implementation of a quality assurance program to insure reliable HER2/neu testing in pathology laboratories.
![Page 20: Biomarkers on tumor tissue: from research to diagnostic tools used in the Clinic](https://reader036.vdocuments.net/reader036/viewer/2022062501/56815cd0550346895dcae1bb/html5/thumbnails/20.jpg)
AETMIS (Agence d’Évaluation des Technologies et des Modes d’Intervention en Santé)
• « Diagnostic Performance of Techniques Used for HER-2 Testing in Breast Cancer »
• recommends the implementation of an HER-2 quality assurance program in Quebec
• At least one reference lab• Internal and external quality controls• Affiliation of every lab to a reference lab• Minimum 250 cases annually• Ongoing training for pathologists and lab
personnel• Central database for evaluation
![Page 21: Biomarkers on tumor tissue: from research to diagnostic tools used in the Clinic](https://reader036.vdocuments.net/reader036/viewer/2022062501/56815cd0550346895dcae1bb/html5/thumbnails/21.jpg)
Challenges for Quality assurance in anatomic pathology in Quebec
• Little hierarchy in service organisation in pathology• Participation to proficiency testing not uniform until recently• Many authorities involved
• Ministry of Health • INSPQ / LSPQ (public health)• Expert committees
• Comité consultatif en anatomopathologie (advisory committee)• Comité d’assurance qualité en pathologie (LSPQ)
• Professional associations (pathology, microbiology, biochemistry etc)
![Page 22: Biomarkers on tumor tissue: from research to diagnostic tools used in the Clinic](https://reader036.vdocuments.net/reader036/viewer/2022062501/56815cd0550346895dcae1bb/html5/thumbnails/22.jpg)
Comité consultatif en anatomopathologie(advisory committee in anatomic pathology)
• Created by the “Direction de la Lutte Contre le Cancer” in summer 2008 following the publication of AETMIS report
• Mandate• Identify current pathology challenges and recommend specific
actions• Develop a quality assurance program for pathology and
recommend actions for quality improvement• Standardize pathology reports for cancer• Propose solutions to overcome staff shortage in pathology
![Page 23: Biomarkers on tumor tissue: from research to diagnostic tools used in the Clinic](https://reader036.vdocuments.net/reader036/viewer/2022062501/56815cd0550346895dcae1bb/html5/thumbnails/23.jpg)
Comité consultatif en anatomopathologie(advisory committee in anatomic pathology)
• At minister Bolduc’s request, work on quality assurance was prioritized
• The Global plan for quality assurance in anatomic pathology was completed in October 2009
• 16 experts were consulted• It was endorsed by the Quebec
college of physicians and the Quebec association of pathologists
• Ministry of Health committed itself to implement the quality assurance program in Québec
![Page 24: Biomarkers on tumor tissue: from research to diagnostic tools used in the Clinic](https://reader036.vdocuments.net/reader036/viewer/2022062501/56815cd0550346895dcae1bb/html5/thumbnails/24.jpg)
Global plan for quality assurance
• Three major Objectives
1. Commitment of the Ministry of Health
2. The program must be mandatory
3. The program must be educational
![Page 25: Biomarkers on tumor tissue: from research to diagnostic tools used in the Clinic](https://reader036.vdocuments.net/reader036/viewer/2022062501/56815cd0550346895dcae1bb/html5/thumbnails/25.jpg)
Global plan for quality assurance
• 20 recommendations• Items covered :
• Internal quality control• Proficiency testing (external quality assurance)• Laboratory designation• Support• Evaluation
![Page 26: Biomarkers on tumor tissue: from research to diagnostic tools used in the Clinic](https://reader036.vdocuments.net/reader036/viewer/2022062501/56815cd0550346895dcae1bb/html5/thumbnails/26.jpg)
Global plan for quality assurance
• Internal quality control• Development of guidelines of good practice in every laboratory
• Tissue preparation and fixation• Technique validation and standardization • Use of positive and negative controls• Interpretation• Quality indicators
![Page 27: Biomarkers on tumor tissue: from research to diagnostic tools used in the Clinic](https://reader036.vdocuments.net/reader036/viewer/2022062501/56815cd0550346895dcae1bb/html5/thumbnails/27.jpg)
Global plan for quality assurance
• Proficiency testing• Mandatory participation to an external quality assurance program• Program development under the responsibility of the “Comité
d’assurance qualité externe en pathologie” (LSPQ)• Preanalytic, analytic and postanalytic phases evaluated• Confidential• Support given to laboratories experiencing difficulties• Progressive implementation• Started in Fall 2010
![Page 28: Biomarkers on tumor tissue: from research to diagnostic tools used in the Clinic](https://reader036.vdocuments.net/reader036/viewer/2022062501/56815cd0550346895dcae1bb/html5/thumbnails/28.jpg)
Global plan for quality assurance
• Laboratory designation• According to the level of complexity of analyses• According to on site expertise• Specific to tumour site • Related to the presence of a cancer interdisciplinary team• Development of accreditation standards specific to pathology• Designation under responsibility of another direction at MSSS
![Page 29: Biomarkers on tumor tissue: from research to diagnostic tools used in the Clinic](https://reader036.vdocuments.net/reader036/viewer/2022062501/56815cd0550346895dcae1bb/html5/thumbnails/29.jpg)
Global plan for quality assurance
• Support• Continuing training (APQ, OPTMQ)• Expert teams in charge of accompanying labs experiencing
difficulties• Development of guidelines and protocols (Breast cancer, colon
cancer)• Development of quality indicators• Prioritization of the replacement of lab equipment
![Page 30: Biomarkers on tumor tissue: from research to diagnostic tools used in the Clinic](https://reader036.vdocuments.net/reader036/viewer/2022062501/56815cd0550346895dcae1bb/html5/thumbnails/30.jpg)
Global plan for quality assurance
• Program evaluation• Implementation• Improvement of quality assurance following implementation
![Page 31: Biomarkers on tumor tissue: from research to diagnostic tools used in the Clinic](https://reader036.vdocuments.net/reader036/viewer/2022062501/56815cd0550346895dcae1bb/html5/thumbnails/31.jpg)
Introduction of new tests on tumor tissue in pathology
• Many new tests are expected in the near future• Pathology laboratories are increasingly involved• Which laboratory should do the test?:
• Any laboratory interested at developing new tests?• Manufacturers which developed the test?• Ministry of health?
![Page 32: Biomarkers on tumor tissue: from research to diagnostic tools used in the Clinic](https://reader036.vdocuments.net/reader036/viewer/2022062501/56815cd0550346895dcae1bb/html5/thumbnails/32.jpg)
Conclusions and future direction
• There is a need to anticipate new diagnostic tests on tumor tissue
• Scientific watch to identify potential new tests (“advance notice”)
• Experts should be asked to recommend reference labs
• Coordination with DLCC and MSSS
![Page 33: Biomarkers on tumor tissue: from research to diagnostic tools used in the Clinic](https://reader036.vdocuments.net/reader036/viewer/2022062501/56815cd0550346895dcae1bb/html5/thumbnails/33.jpg)